Robert McClay

Robert McClay, PMP, is a Director of Small Molecule Co-Development at Pfizer, where they focus on developing innovative pharmaceutical assets. They have extensive experience in the pharmaceutical industry, having previously held leadership positions at Pfizer and AstraZeneca, where they oversaw product industrialization and launch operations. Robert's expertise includes project management, regulatory compliance, and commercialization of new products, with notable achievements such as the development of Paxlovid during the COVID-19 pandemic. They hold a BS in Bioengineering from Syracuse University and are currently pursuing education at Villanova University.